Clinical trial
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01486849 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Cytokinetics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- March 31, 2012
- Enrollment
- 27 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.